PMID: 9531332Apr 8, 1998Paper

Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto

British Journal of Haematology
L PaganoF Mandelli

Abstract

Between 1983 and 1994 the incidence of secondary haematological neoplasms (SHM) was evaluated in 1170 new cases of ALL enrolled in the GIMEMA trials. Of the 942 patients who achieved complete remission (CR); seven developed a SHM: four AMLs and three NHLs. The median latency from onset of ALL and of secondary haematological neoplasm was 69 months for AML and 61 months for NHL. Three out of four patients with secondary AML were unresponsive to the new chemotherapy and died, whereas the fourth patient achieved a new CR. Among the three NHL cases, two patients are presently alive in CR, whereas the third patient was refractory to chemotherapy and died. The relative risk of haematological malignancy among the GIMEMA trials population, as compared to that of the Italian Cancer Registries, was 15.25-fold higher, and the actuarial estimated cumulative proportion of ALL patients with a secondary haematological neoplasm at 5 and 10 years were 0.59% and 3.63% respectively. The incidence of adult ALL who developed a SHM, although apparently lower than in the paediatric ALL series, was higher when compared to the normal population. The difference between paediatric and adult ALL is probably due to the lack of craniospinal radiotherapy and ...Continue Reading

References

Aug 1, 1979·American Journal of Clinical Pathology·G SpectorS J Culbert
Dec 1, 1979·American Journal of Clinical Pathology·M L BaldwinR L Ridolfi
Apr 1, 1978·The American Journal of Medicine·D P Skoog, J R Feagler
Nov 7, 1991·The New England Journal of Medicine·J P NegliaG D Hammond
Dec 12, 1991·The New England Journal of Medicine·C H PuiJ T Sandlund
Sep 21, 1989·The New England Journal of Medicine·R P WitherspoonR Storb
Jul 20, 1989·The New England Journal of Medicine·C H PuiS B Murphy
Feb 26, 1987·The New England Journal of Medicine·J KereA de la Chapelle
Aug 15, 1988·International Journal of Cancer. Journal International Du Cancer·J W van der VeldenC Lagarde
Aug 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G A Omura, M Raney
Jul 1, 1985·Cancer Genetics and Cytogenetics·H Van den BergheG Tricot
Aug 1, 1969·The American Journal of Medicine·B S Clark, P J Dawson
May 1, 1980·American Journal of Clinical Pathology·S TrubowitzS Davis
Jan 1, 1981·Clinical Cardiology·D BallantyneF C Ballantyne
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R LowskyH Messner
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M JankovicP Macchia
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J WinickG R Buchanan
Mar 1, 1996·British Journal of Haematology·F MandelliB Rotoli

❮ Previous
Next ❯

Citations

Oct 24, 2000·Leukemia & Lymphoma·G VisaniS Tura
May 30, 2001·Leukemia & Lymphoma·G LeoneL Pagano
Jan 16, 2009·International Journal of Laboratory Hematology·V ShivarovM Guenova
Jan 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitrios ChristoulasChristos A Papadimitriou
Jun 9, 2004·Critical Reviews in Oncology/hematology·Renato BassanRoel Willemze
Nov 16, 2021·Blood Research·Smeeta GajendraManorama Bhargava

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.